Phase Bioscience is a biotechnology firm that has developed a technology utilizing genetically-engineered biopolymer peptides (ELPs) that changes solubility (from a liquid to a solid and back) based on the temperature and the salt content of the solution. Known as deltaPhase, Phase Bioscience's ELPs are designed to be used by pharmaceutical researchers in drug discovery processes and in life science applications, including recombinant protein purification (isolating a particular protein in a solution) and enzyme biocatalysts (isolating a particular recombinant enzyme in a solution).

Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide. It develops, produces, markets, and distributes therapies for the people suffering from chronic and acute, immune deficiency disorders, alpha-1 antitrypsin deficiency, infectious diseases, hemophilia, and severe burns. The company's products include Gamunex, an intravenous immune globulin (IGIV) for the treatment of primary immune deficiency and autoimmune diseases; and Prolastin, an alpha-1 proteinase inhibitor (A1PI) for the treatment of alpha-1 antitrypsin deficiency-related emphysema. It also offers Hypermunes, which are antibody preparations for hepatitis, rabies, tetanus, and treatment of Rh negative women pregnant with Rh positive children; and albumin under various brand names, including Plasbumin albumin and Plasmanate plasma protein factor. Talecris Biotherapeutics Holdings Corp. is headquartered in Research Triangle Park, North Carolina.

The National Institutes of Health (NIH), through its own research and the distribution of grants, seeks to understand disease inside and out. Part of the US Department of Health and Human Services, the NIH is the government's main medical research entity. It comprises 27 institutes and centers covering every medical discipline, from general medical sciences to alternative therapies. The organization has nearly 6,000 scientists of its own and gives out some 50,000 grants to researchers at more than 3,000 universities, hospitals, and research labs in all 50 states. Among its vast array of projects, NIH has supported efforts to develop an AIDS vaccine, map human genetic variation, and study avian flu.

Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights.

Lipoxen Plc, a biopharmaceutical company, develops drug and vaccine delivery systems, and proprietary products in the fields of protein drugs, vaccines, and oncology. The company’s product candidates under development include ErepoXen for the treatment to maintain the red blood cell population and prevent anaemia; StimuXen for the treatment of neutropenia; InferoXen for hepatitis C; SuliXen for the treatment of type II diabetes; LipoNeu for streptococcus pneumoniae; LipoTet, an oral liposomal tetanus vaccine; HepaXen to prevent and treat hepatitis B; LipoRab, a rabies vaccine candidate; and LipoTaxen, an anti-cancer drug for the treatment of lung, breast, ovarian, and other cancers. It has operations in the United States, Europe, and India. Lipoxen Plc has a collaboration agreement with Pharmsynthez JSC. The company is based in London, the United Kingdom.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

Elan Corporation, plc company was founded in 1969 and is headquartered in Dublin, Ireland. Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan’s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).

Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania. Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest in Matrix Laboratories Limited (Matrix). Through Matrix, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Mylan markets more than 570 products to consumers in more than 140 countries. Mylan’s products cover an array of therapeutic categories, and offer a range of dosage forms and delivery systems, including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. On June 2, 2008, the Company acquired Merck KGaA’s Central & Eastern Europe (CEE) generics businesses.

Calypte Biomedical Corporation company was founded in 1988 and is headquartered in Portland, Oregon. Calypte Biomedical Corporation engages in the development, manufacture, and distribution of in vitro diagnostic tests primarily for the diagnosis of human immunodeficiency virus (HIV) infection. It focuses on the commercialization of HIV-1/2 rapid tests for the detection of antibodies to HIV-1 and HIV 2 in oral fluid and blood samples using a lateral flow dipstick design. The company also offers HIV-1 BED Incidence EIA Test, which detects HIV-1 infections that have occurred within approximately the prior six months, and could be used by public health agencies to identify those regions and the populations within them where HIV transmission is occurring most recently. Calypte Biomedical, through its 51%-owned joint ventures, Beijing Calypte Biomedical Technology Ltd. and Beijing Marr Bio-Pharmaceutical Co., Ltd., manufactures and markets its products in China.

ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.